Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 2 diabetes mellitus (T2DM) with HbA1c ≥ 8.0% and ≤ 12.0%~* Stable metformin therapy dose of ≥ 1500mg for at least 8 weeks prior to screening~* Body mass index (BMI) ≤ 45.0kg/m2~Exclusion Criteria:~* Estimated glomerular filtration rate (eGFR) \< 60mL/min/1,73m2 and Serum Creatinine (Scr) ≥ 1.5 mg/dL in males or ≥ 1.4 mg/dL in females~* Uncontrolled hypertension Systolic Blood Pressure (SBP) ≥ 160mmHg and/or Diastolic Blood Pressure (DBP) ≥ 100mmHg~* Hepatic disease~* Cardiovascular disease within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Saxagliptin+Metformin XR+Placebo (Type: ACTIVE_COMPARATOR): None
- Arm 2: Dapagliflozin+Metformin XR+Placebo (Type: ACTIVE_COMPARATOR): None
- Arm 3: Saxagliptin+Dapagliflozin+Metformin XR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).